Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
chemotherapy
immune biomarker
immune monitoring
immunotherapy
lung cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
12
2019
accepted:
29
04
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The landscape for medical treatment of lung cancer has irreversibly changed since the development of immuno-oncology (IO). Yet, while immune checkpoint blockade (ICB) revealed that T lymphocytes play a major role in lung cancer, the precise dynamic of innate and adaptive immune cells induced by anticancer treatments including chemotherapy, targeted therapy, and/or ICB is poorly understood. In lung cancer, studies evaluating specific immune cell populations as predictors of response to medical treatment are scarce, and knowledge is fragmented. Here, we review the different techniques allowing the detection of immune cells in the tumor and blood (multiplex immunohistochemistry and immunofluorescence, RNA-seq, DNA methylation pattern, mass cytometry, functional tests). In addition, we present data that consider different baseline immune cell populations as predictors of response to medical treatments of lung cancer. We also review the potential for assessing dynamic changes in cell populations during treatment as a biomarker. As powerful tools for immune cell detection and data analysis are available, clinicians and researchers could increase understanding of mechanisms of efficacy and resistance in addition to identifying new targets for IO by developing translational studies that decipher the role of different immune cell populations during lung cancer treatments.
Identifiants
pubmed: 32670271
doi: 10.3389/fimmu.2020.01036
pmc: PMC7327092
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1036Subventions
Organisme : NCI NIH HHS
ID : R01 CA208403
Pays : United States
Informations de copyright
Copyright © 2020 Rochigneux, Garcia, Chanez, Madroszyk, Olive and Garon.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Methods Mol Biol. 2011;733:223-38
pubmed: 21431774
Science. 2016 Aug 26;353(6302):925-8
pubmed: 27471252
Nat Methods. 2012 Jan 30;9(2):145-51
pubmed: 22290186
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Cancer Res. 2016 Apr 15;76(8):2153-65
pubmed: 27197252
J Immunol. 2007 Oct 1;179(7):4323-34
pubmed: 17878327
Expert Rev Mol Diagn. 2015;15(9):1171-86
pubmed: 26289603
BMC Bioinformatics. 2012 May 08;13:86
pubmed: 22568884
Cancer Immunol Immunother. 2013 Sep;62(9):1439-51
pubmed: 23760662
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Cell. 2015 May 21;161(5):1202-1214
pubmed: 26000488
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
J Clin Pathol. 1978 May;31(5):454-60
pubmed: 77279
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Immunology. 1968 Feb;14(2):181-96
pubmed: 4966657
Nat Rev Drug Discov. 2020 Mar;19(3):163-164
pubmed: 32127660
Nat Chem Biol. 2008 Feb;4(2):132-42
pubmed: 18157122
Lancet Oncol. 2016 Mar;17(3):259-260
pubmed: 26858123
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
J Cancer. 2017 Aug 23;8(14):2846-2853
pubmed: 28928874
Cancer Immunol Immunother. 2013 Mar;62(3):471-9
pubmed: 22986452
Cell Rep. 2016 Nov 15;17(8):2101-2111
pubmed: 27851971
Nature. 2018 Dec;564(7736):439-443
pubmed: 30405246
Methods Mol Biol. 2014;1186:75-86
pubmed: 25149304
Cell. 2016 May 5;165(4):780-91
pubmed: 27153492
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
J Exp Med. 1968 Nov 1;128(5):1157-81
pubmed: 5682942
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
Clin Lung Cancer. 2017 Sep;18(5):444-459.e1
pubmed: 28416123
Nat Rev Drug Discov. 2017 Apr;16(4):264-272
pubmed: 28057932
Int Immunol. 2013 Feb;25(2):129-37
pubmed: 23087177
JAMA. 2017 Dec 12;318(22):2199-2210
pubmed: 29234806
Expert Rev Mol Diagn. 2014 Jan;14(1):67-81
pubmed: 24308362
Cancer Immunol Immunother. 2012 Oct;61(10):1849-56
pubmed: 22456757
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Clin Chem. 2002 Oct;48(10):1819-27
pubmed: 12324512
Cell. 2016 Oct 6;167(2):566-580.e19
pubmed: 27716510
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Curr Protoc Immunol. 2017 Aug 1;118:7.42.1-7.42.12
pubmed: 28762488
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Expert Rev Vaccines. 2010 Jun;9(6):601-16
pubmed: 20518716
Immunol Cell Biol. 2007 Jun;85(4):295-9
pubmed: 17453010
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nat Immunol. 2017 Oct;18(10):1160-1172
pubmed: 28783152
Am J Pathol. 2018 Jan;188(1):242-251
pubmed: 29037854
JAMA Oncol. 2019 Jul 18;:
pubmed: 31318407
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nat Commun. 2018 Aug 10;9(1):3196
pubmed: 30097571
Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):329-37
pubmed: 19318915
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Sci Immunol. 2016 Jul 14;1(1):aaf6925
pubmed: 28783673
Neoplasia. 2019 Mar;21(3):282-293
pubmed: 30743162
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
BMC Immunol. 2017 Mar 7;18(1):14
pubmed: 28270111
Nature. 2010 Sep 16;467(7313):338-42
pubmed: 20720541
Cells. 2012 May 10;1(2):111-26
pubmed: 24710418
JAMA Oncol. 2019 Aug 22;:
pubmed: 31436822
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
pubmed: 19572148
J Thorac Oncol. 2016 Aug;11(8):1263-1272
pubmed: 27178984
Nat Biotechnol. 2011 Oct 02;29(10):886-91
pubmed: 21964415
Front Immunol. 2018 Jul 26;9:1672
pubmed: 30093901
Cytometry A. 2016 May;89(5):480-90
pubmed: 27059253
Cytometry A. 2015 Nov;87(11):982-5
pubmed: 26349004
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Nature. 2014 May 15;509(7500):371-5
pubmed: 24739965
Front Oncol. 2019 May 17;9:415
pubmed: 31165047
Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36
pubmed: 22955317
Trends Immunol. 2012 Jul;33(7):323-32
pubmed: 22476049
Immunity. 2012 Jan 27;36(1):142-52
pubmed: 22265676
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Cell Rep. 2015 Mar 3;10(8):1386-97
pubmed: 25732828
Cell Syst. 2016 Oct 26;3(4):385-394.e3
pubmed: 27693023
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nat Commun. 2018 Feb 28;9(1):884
pubmed: 29491377
Eur J Immunol. 2017 Oct;47(10):1584-1797
pubmed: 29023707
Int Immunol. 2018 Feb 3;30(1):13-22
pubmed: 29294043
Chest. 2012 Jun;141(6):1466-1472
pubmed: 21940774
Cancer Res. 2019 Mar 15;79(6):1214-1225
pubmed: 30541742
Clin Cancer Res. 2018 Aug 15;24(16):3857-3866
pubmed: 29716923
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11982-7
pubmed: 23818604
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Wiley Interdiscip Rev RNA. 2017 Jan;8(1):
pubmed: 27198714
World J Oncol. 2017 Dec;8(6):180-187
pubmed: 29317963
Lung Cancer. 2016 Mar;93:9-16
pubmed: 26898608
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Proc Natl Acad Sci U S A. 1957 Jan 15;43(1):122-8
pubmed: 16589984
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
Nat Rev Immunol. 2018 Jan;18(1):35-45
pubmed: 28787399
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Eur J Cancer. 2016 Jul;61:77-84
pubmed: 27155446
J Clin Oncol. 2016 Apr 10;34(11):1223-30
pubmed: 26834066